Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD40
  • Lymphoma, Non-Hodgkin

abstract

  • Dacetuzumab monotherapy was well tolerated in patients with NHL in doses up to 8 mg/kg/wk. Preliminary response data are encouraging and support additional studies of dacetuzumab in this patient population.

publication date

  • September 10, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2008.21.3017

PubMed ID

  • 19636010

Additional Document Info

start page

  • 4371

end page

  • 7

volume

  • 27

number

  • 26